Clinical trial · Interventional
MRI-Guided Biopsy of Recurrent Prostate Cancer After Radiotherapy
MRI - Guided Biopsy for Suspicion of Locally Recurrent Prostate Cancer After External Beam Radiotherapy
NCT00775866CI-TRIAL-00030572completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study we will test a new procedure to guide needle biopsies into the prostate gland based on MRI. This study will be conducted in patients who may have recurrence of their cancer in the prostate gland after radiation therapy in order to map out the location of the recurrence. Using this technique, we will be able to measure the accuracy of MR images in identifying the site of tumour recurrence.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Recurrent Prostate Cancer | Malignant Prostate Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MRI-Guided Biopsy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- MRI guided prostate biopsy
- interventionNames
- Procedure: MRI-Guided Biopsy
Primary outcomes (1)
- measure
- The primary endpoint is a preliminary estimate of the diagnostic accuracy of MRI in identifying sites of recurrent tumor after radiotherapy for prostate cancer.
- timeFrame
- at the end of the evaluation phase
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Biochemical failure \> 18 months after definitive external beam radiotherapy (ASTRO definition - revised version 2006: rise by 2 ng/mL or more above the nadir PSA) * PSA \<20 prior to initial course of external beam radiotherapy * PSADT \>3 months at failure * Age ≥ 18 years * ECOG performance status 0 or 1 with \>10 year life expectancy * Fit for local anaesthesia * Informed consent: Exclusion Criteria: * Contraindications to MRI * Severe claustrophobia * Bleeding diathesis and anti-coagulative therapy that cannot be temporarily ceased precluding brachytherapy * Previous brachytherapy * Active hormonal therapy * Radiologic evidence of LN or distant metastases * Other urinary or medical conditions deemed by the PI or associates to make the patient ineligible for MRI-guided prostate biopsy. * Contraindications to endorectal coil, surgically absent rectum, severe hemorrhoids or previous colorectal surgery * Contraindications to conscious sedation * Contraindication to IV Gadolinium administration * latex allergy
References
Publications (1)
- BACKGROUNDMenard C, Iupati D, Publicover J, Lee J, Abed J, O'Leary G, Simeonov A, Foltz WD, Milosevic M, Catton C, Morton G, Bristow R, Bayley A, Atenafu EG, Evans AJ, Jaffray DA, Chung P, Brock KK, Haider MA. MR-guided prostate biopsy for planning of focal salvage after radiation therapy. Radiology. 2015 Jan;274(1):181-91. doi: 10.1148/radiol.14122681. Epub 2014 Sep 8. PMID 25203127